| Not Yet Recruiting | Effect of Fu's Subcutaneous Needling for Age-related Macular Degeneration NCT07121127 | Zhiming Yan | EARLY_Phase 1 |
| Enrolling By Invitation | Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic So NCT07456826 | Harrow Inc | Phase 4 |
| Not Yet Recruiting | Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration NCT05780931 | VA Office of Research and Development | — |
| Recruiting | Enhanced Vision and Imaging Tests for Enabling Treatment Trials in Early and Intermediate AMD NCT07515521 | Maximilian Pfau | — |
| Not Yet Recruiting | Wide Field OCTA in Ocular Diseases NCT07298174 | IRCCS San Raffaele | — |
| Not Yet Recruiting | High-throughput Large-model-based AI-assisted Diagnosis Using OCT NCT07249307 | Peking Union Medical College Hospital | — |
| Recruiting | Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD NCT06659445 | ONL Therapeutics | Phase 2 |
| Recruiting | Artificial Intelligence-Aided Screening for Patients With Diabetic Retinopathy and Age-related Macular Degener NCT07069647 | National Taiwan University Hospital | N/A |
| Recruiting | International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bila NCT07164378 | VisionCare, Inc. | N/A |
| Recruiting | EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational NCT07434713 | Insel Gruppe AG, University Hospital Bern | — |
| Recruiting | Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic D NCT06843499 | National Taiwan University Hospital | N/A |
| Not Yet Recruiting | Functional Assessments in Vision Impairment NCT06908161 | Center for Eye Research Australia | — |
| Not Yet Recruiting | Study of JMKX003948 Ophthalmic Suspension in Healthy Participants NCT06832657 | Jemincare | Phase 1 |
| Recruiting | A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone NCT06541704 | Regeneron Pharmaceuticals | Phase 3 |
| Recruiting | Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular D NCT07084883 | iHealthScreen Inc | — |
| Recruiting | Active AMD Study to Improve Function in Veterans NCT05932069 | VA Office of Research and Development | N/A |
| Recruiting | Proteomic Biomarker Identification in AMD, Diabetic Retinopathy and Retinal Detachment NCT07500324 | Fondazione G.B. Bietti, IRCCS | N/A |
| Completed | Prevalence and Determinants of Shoulder Girdle Musculoskeletal Complaints in Geriatric Patients With Diminishe NCT07206654 | Beni-Suef University | — |
| Enrolling By Invitation | ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Se NCT05481827 | Gyroscope Therapeutics Limited | Phase 2 |
| Recruiting | Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy NCT04292080 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Withdrawn | Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related NCT04697953 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Pat NCT05066685 | Novartis Pharmaceuticals | — |
| Completed | Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Ma NCT05146687 | Novartis Pharmaceuticals | — |
| Completed | Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Mac NCT05110209 | Novartis Pharmaceuticals | — |
| Completed | Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration NCT05111743 | Novartis Pharmaceuticals | — |
| Completed | Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration NCT05082415 | Novartis Pharmaceuticals | — |
| Completed | Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of B NCT05037396 | Novartis Pharmaceuticals | — |
| Unknown | Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is P NCT03690505 | University Hospital, Limoges | N/A |
| Unknown | Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration NCT03577041 | Centre Hospitalier Universitaire, Amiens | — |
| Unknown | Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease P NCT03859245 | Bristlecone Health, Inc. | N/A |
| Active Not Recruiting | Development of Novel Clinical Endpoints in Intermediate AMD NCT03349801 | Frank G. Holz | — |
| Completed | Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada NCT02585401 | Bayer | — |
| Completed | Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascula NCT02611778 | Bioeq GmbH | Phase 3 |
| Completed | Production of iPSC Derived RPE Cells for Transplantation in AMD NCT02464956 | Moorfields Eye Hospital NHS Foundation Trust | — |
| Terminated | Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular De NCT02398500 | Alcon Research | Phase 1 / Phase 2 |
| Completed | Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device NCT02445313 | Doheny Image Reading Center | — |
| Terminated | X-82 to Treat Age-related Macular Degeneration NCT02348359 | Tyrogenex | Phase 2 |
| Completed | Evaluating the Relationship Between Function and Structure in ARCHER II-like Population Using Data From a Natu NCT07424235 | IRCCS Ospedale San Raffaele | — |
| Completed | Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD NCT02022540 | PanOptica, Inc. | Phase 1 |
| Completed | Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration NCT02121353 | Pfenex, Inc | Phase 1 / Phase 2 |
| Completed | Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degenerat NCT01722045 | Regeneron Pharmaceuticals | Phase 4 |
| Completed | Intervention Trial in Early Age-related Macular Degeneration NCT01694680 | Newtricious R&D BV | N/A |
| Completed | A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD) NCT01542866 | Novartis Pharmaceuticals | N/A |
| Completed | Intravitreal Injection Anesthesia - Comparison of Different Topical Agents NCT01224847 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | N/A |
| Completed | Genetics and Markers of Degenerative and Inflammatory Eye Diseases NCT00647439 | National Eye Institute (NEI) | — |
| Terminated | A Study Of Early Markers Of Choroidal Neovascularization NCT00902785 | Pfizer | — |
| Terminated | An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascula NCT00327470 | Pfizer | Phase 4 |
| Unknown | A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subje NCT00354445 | Eyetech Pharmaceuticals | Phase 4 |